MCID: RBL001
MIFTS: 57

Rubella malady

Categories: Rare diseases, Infectious diseases, Fetal diseases, Neuronal diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 41 rubella is an infection caused by a virus. it is usually mild with fever and a rash. about half of the people who get rubella do not have symptoms. if you do get them, symptoms may include a rash that starts on the face and spreads to the body mild fever aching joints, especially in young women swollen glands rubella is most dangerous for a pregnant woman's baby. it can cause miscarriage or birth defects. rubella spreads when an infected person coughs or sneezes. people without symptoms can still spread it. there is no treatment, but the measles-mumps-rubella (mmr) vaccine can prevent it. centers for disease control and prevention

MalaCards based summary : Rubella, also known as german measles, is related to hepatitis and aseptic meningitis, and has symptoms including rash on the face which spreads to the trunk, fever and lymphadenopathy. An important gene associated with Rubella is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Vaccines and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and brain, and related phenotype is Increased shRNA abundance.

Disease Ontology : 12 A viral infectious disease that results_in infection located in skin, has material basis in Rubella virus, which is transmitted_by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted_by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in an developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 71 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.1 HLA-A HLA-B HLA-DRB1 TNF
2 aseptic meningitis 30.0 HLA-A HLA-B HLA-DRB1 TNF
3 tuberculosis 29.3 CD40LG IL4 TNF
4 status epilepticus 29.3 IL4 MOG TNF
5 congenital rubella 12.5
6 rubella panencephalitis 11.9
7 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.8
8 measles 11.5
9 mumps 11.3
10 acute disseminated encephalomyelitis 11.2
11 cytomegalic inclusion disease 11.0
12 microcephaly 10.9
13 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 10.7
14 acute hemorrhagic leukoencephalitis 10.7
15 togaviridae disease 10.7
16 immune-mediated encephalomyelitis 10.7
17 postinfectious encephalomyelitis 10.7
18 apple allergy 10.3 HLA-DQB1 HLA-DRB1
19 hemoglobin d disease 10.3 HLA-DQB1 HLA-DRB1
20 solid pseudopapillary carcinoma of pancreas 10.3 HLA-A HLA-B
21 caplan's syndrome 10.2 HLA-DPB1 HLA-DRB1
22 lin-gettig syndrome 10.2 HLA-DQB1 HLA-DRB1
23 midline interhemispheric variant of holoprosencephaly 10.2 HLA-DQB1 HLA-DRB1
24 myopathy, congenital nonprogressive, with moebius sequence and robin sequence 10.2 HLA-A HLA-B
25 hypopituitarism 10.2 CD40LG HLA-B HLA-DPB1
26 niemann-pick disease 10.2 HLA-DPB1 HLA-DRB1 MOG
27 tubular renal disease-cardiomyopathy syndrome 10.2 IL4 TNF
28 rete testis adenocarcinoma 10.2 HLA-A HLA-DQB1
29 immune deficiency, familial variable 10.2 HLA-B HLA-DQB1 HLA-DRB1
30 epididymo-orchitis 10.2 HLA-A HLA-B
31 human immunodeficiency virus infectious disease 10.2 CD40LG HLA-DRB1 TNF
32 pancreatic signet ring cell adenocarcinoma 10.2 CD40LG HLA-DRB1 TNF
33 autosomal dominant intermediate charcot-marie-tooth 10.2 HLA-DQB1 HLA-DRB1 TNF
34 hereditary alpha tryptasemia syndrome 10.2 CD40LG HLA-DRB1 TNF
35 benign deep fibrous histiocytoma 10.2 CD40LG HLA-DRB1 TNF
36 endogenous depression 10.2 CD40LG HLA-DRB1 TNF
37 plummer's disease 10.2 CD40LG HLA-DRB1 TNF
38 pulmonary hemosiderosis 10.2 HLA-DRB1 MOG TNF
39 anthracosis 10.2 CD40LG HLA-A HLA-DPB1
40 t-cell prolymphocytic leukemia 10.2 HLA-DQB1 TNF
41 immunoglobulin g deficiency 10.2 CD40LG HLA-DRB1 TNF
42 lagophthalmos 10.2 IL4 TNF
43 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.2 HLA-B HLA-DQB1 TNF
44 low anorectal malformation 10.2 HLA-DQB1 HLA-DRB1 TNF
45 mirizzi syndrome 10.2 HLA-B HLA-DRB1 TNF
46 diabetic angiopathy 10.2 CD40LG IL4
47 barbiturate abuse 10.2 CD40LG HLA-DQB1 IL4
48 swine influenza 10.1 HLA-B HLA-DRB1 TNF
49 celiac disease 10.1 CD40LG HLA-B TNF
50 sacral nerve root cysts 10.1 HLA-A HLA-B HLA-DRB1

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

Symptoms:

12
  • rash on the face which spreads to the trunk
  • fever
  • lymphadenopathy
  • joint pains
  • headache
  • conjunctivitis

UMLS symptoms related to Rubella:


exanthema, fever, pruritus

GenomeRNAi Phenotypes related to Rubella according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 8.92 HLA-B HLA-DPB1 HLA-DQB1 IL4

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
2 Immunoglobulins Phase 4,Phase 2,Phase 1
3 Antibodies Phase 4,Phase 2,Phase 1
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
5 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4
7
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
8
Aluminum hydroxide Approved Phase 3,Phase 2 21645-51-2
9
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
10
Lactitol Phase 3,Phase 2 585-86-4 3871
11 PENTA Phase 3,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 2
13 Anti-Infective Agents Phase 3,Phase 2
14 Trace Elements Phase 3
15 Vitamins Phase 3
16 Protective Agents Phase 3,Phase 2
17 Retinol palmitate Phase 3
18 Micronutrients Phase 3
19 Antioxidants Phase 3
20 retinol Nutraceutical Phase 3
21
Altretamine Approved Phase 2 645-05-6 2123
22
Mycophenolic acid Approved Phase 2 24280-93-1 446541
23
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
24
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
25
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
26
Obinutuzumab Approved Phase 2,Phase 1 949142-50-1
27
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
28 Fibrinolytic Agents Phase 2
29 Anticoagulants Phase 2
30 Prednisolone acetate Phase 2
31 glucocorticoids Phase 2
32 Gastrointestinal Agents Phase 2
33 Neuroprotective Agents Phase 2
34 Hormone Antagonists Phase 2
35 Hormones Phase 2
36 Peripheral Nervous System Agents Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
38 Prednisolone hemisuccinate Phase 2
39 Prednisolone phosphate Phase 2
40 Immunosuppressive Agents Phase 2
41 Antiemetics Phase 2
42 Anti-Inflammatory Agents Phase 2
43 Antibiotics, Antitubercular Phase 2
44 Methylprednisolone acetate Phase 2
45 Methylprednisolone Hemisuccinate Phase 2
46 Autonomic Agents Phase 2
47 Antineoplastic Agents, Hormonal Phase 2
48 Immunoglobulin G Phase 1
49 Immunoglobulin M Phase 1
50 Autoantibodies Phase 1

Interventional clinical trials:

(show top 50) (show all 133)
id Name Status NCT ID Phase
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
3 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
4 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
5 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
6 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
7 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
8 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
9 Measles, Mumps, and Rubella (MMR) Immunity in College Students Completed NCT00962819 Phase 4
10 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
11 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
12 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
13 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
14 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4
15 MMR and Varicella Vaccine in Premature Infants Completed NCT00156559 Phase 4
16 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
17 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
18 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
19 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Recruiting NCT02880865 Phase 4
20 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
21 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
22 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Active, not recruiting NCT02325310 Phase 4
23 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
24 Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines Terminated NCT00138255 Phase 4
25 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
26 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
27 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
28 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
29 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
30 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
31 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
32 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
33 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
34 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
35 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
36 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
37 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
38 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
39 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
40 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
41 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
42 ProQuad® rHA Safety Completed NCT00560755 Phase 3
43 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
44 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
45 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
46 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly Completed NCT00432042 Phase 3
47 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
48 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3
49 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
50 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3

Search NIH Clinical Center for Rubella

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

MalaCards organs/tissues related to Rubella:

39
Skin, Eye, Brain, Heart, Lymph Node, Testes, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Rubella:

18
Skin

Publications for Rubella

Articles related to Rubella:

(show top 50) (show all 1244)
id Title Authors Year
1
Hospital-based surveillance of congenital rubella syndrome in Indonesia. ( 28091778 )
2017
2
Susceptibility of Rubella Among Pregnant Women Attending the Antenatal Clinic in a Tertiary Care Hospital, Jabalpur, Central India. ( 27925863 )
2017
3
Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )
2017
4
FUNDUS AUTOFLUORESCENCE IN RUBELLA RETINOPATHY: Correlation With Photoreceptor Structure and Function. ( 28005720 )
2017
5
Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. ( 27810866 )
2017
6
The end of measles and congenital rubella: an achievable dream? ( 28067934 )
2017
7
Economic impact of switching rubella IgG methodologies to the prenatal public health program in Alberta. ( 27567094 )
2016
8
Mumps Outbreak at a University and Recommendation for a Third Dose of Measles-Mumps-Rubella Vaccine - Illinois, 2015-2016. ( 27467572 )
2016
9
Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants. ( 27822935 )
2016
10
Global measles and rubella laboratory network support for elimination goals, 2010a892015. ( 27156255 )
2016
11
Assessing immunity to rubella virus: a plea for standardization of IgG (immuno)assays. ( 27147722 )
2016
12
Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. ( 27163657 )
2016
13
Analysis of complete genomes of the rubella virus genotypes 1E and 2B which circulated in China, 2000-2013. ( 27959338 )
2016
14
Zika Virus Is More Like Rubella Than Human Immunodeficiency Virus-Reply. ( 27617894 )
2016
15
Measles and Rubella Seroprevalence Among HIV-Infected And Uninfected Zambian Youth. ( 27879554 )
2016
16
Congenital Rubella. ( 27732820 )
2016
17
Using the two-source capture-recapture method to estimate the incidence and case ascertainment of congenital rubella syndrome in Australia, 1993-2013. ( 27757254 )
2016
18
Corrigendum to "Evaluation of sensitivity of TaqMan RT-PCR for rubella virus detection in clinical specimens" [J. Clin. Virol. 80 (2016) 98-101]. ( 27523613 )
2016
19
Epidemiology of rubella virus cases in the pre-vaccination era of Ethiopia, 2009-2015. ( 27863513 )
2016
20
Vaccine-Preventable Diseases In Pediatric Patients: A Review Of Measles, Mumps, Rubella, And Varicella. ( 27893360 )
2016
21
Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015. ( 27449329 )
2016
22
Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy. ( 27866768 )
2016
23
An outbreak investigation of congenital rubella syndrome in Solomon Islands, 2013. ( 27757248 )
2016
24
Vaccination in secondary school students expedites rubella control and prevents congenital rubella syndrome. ( 27899091 )
2016
25
Spectral Domain-Optical Coherence Tomography Findings in Unilateral Rubella Retinopathy. ( 27579589 )
2016
26
Measles & rubella outbreaks in Maharashtra State, India. ( 27121521 )
2016
27
Global Measles and Rubella Laboratory Network Support for Elimination Goals, 2010-2015. ( 27148917 )
2016
28
Measles-Mumps-Rubella vaccine for children with egg allergy: Is admission for inpatient vaccination necessary? ( 27770112 )
2016
29
Congenital Rubella Syndrome: A Case Report on Changes in Viral Load and Rubella Antibody Titers. ( 27244797 )
2016
30
Calcium-dependent Rubella Virus Fusion Occurs in Early Endosomes. ( 27122589 )
2016
31
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman. ( 27195163 )
2016
32
Introduction of rubella-containing-vaccine to Madagascar: implications for roll-out and local elimination. ( 27122178 )
2016
33
Localization of Viral Antigens Improves Understanding of Congenital Rubella Syndrome Pathophysiology. ( 26870811 )
2016
34
Anti-rubella, Mumps and Measles IgG Antibodies in Medical Students of Tehran University. ( 27424140 )
2016
35
Scale-Free Distribution of Local Infection Cluster Sizes of Measles, Rubella, Syphilis and HIV/AIDS: Correlation with Size Distribution of Municipality Population That Was Also Scale-Free. ( 27169948 )
2016
36
Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh. ( 27519586 )
2016
37
Antiviral activity of hemolymph of Podalia against rubella virus. ( 27896559 )
2016
38
Psychiatric manifestations of congenital rubella syndrome: A case report and review of literature. ( 27606025 )
2016
39
Is birth cohort 1985/9-1990/8 a susceptibility window for congenital rubella syndrome in Taiwan? ( 27343317 )
2016
40
Laboratory confirmation of rubella infection in suspected measles cases. ( 27018071 )
2016
41
Aseptic meningitis after measles-mumps-rubella (MMR) vaccination. ( 27181175 )
2016
42
Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand. ( 27138005 )
2016
43
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
44
Rubella Immunity in Pregnant Native Taiwanese and Immigrants from Asian Countries. ( 27895276 )
2016
45
Fetal malformation in maternal toxoplasma and rubella co-infection in Cameroon: a case report. ( 27912790 )
2016
46
High levels of susceptibility to measles, mumps and rubella (MMR) in HIV-infected individuals in Ireland. ( 27118245 )
2016
47
A case of congenital rubella syndrome and infection in South-East London in 2015: prevention, diagnosis, and the public health response. ( 27884915 )
2016
48
A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process. ( 27149048 )
2016
49
Mumps, measles and rubella vaccination in children with PFAPA syndrome. ( 27997341 )
2016
50
Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. ( 27613149 )
2016

Variations for Rubella

Expression for Rubella

Search GEO for disease gene expression data for Rubella.

Pathways for Rubella

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
2
Show member pathways
13.33 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
3
Show member pathways
13.01 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
4
Show member pathways
12.62 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
5
Show member pathways
12.58 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10RB IL4
6
Show member pathways
12.53 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10RB IL4 TNF
7
Show member pathways
12.47 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TRIM22
8 12.42 C1QBP CD40LG IL4 TNF
9
Show member pathways
12.4 HLA-A HLA-B IL4 TNF
10 12.24 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10RB
11 12.21 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
12 12.17 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10RB TNF
13
Show member pathways
12.09 HLA-A HLA-B IL4 TNF
14 12.06 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
15
Show member pathways
12.06 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
16 12.01 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
17 11.95 CD40LG HLA-A HLA-B
18 11.88 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL4 TNF
19
Show member pathways
11.87 HLA-A HLA-DRB1 IL4
20
Show member pathways
11.85 HLA-DPB1 HLA-DQB1 HLA-DRB1
21 11.81 HLA-DPB1 HLA-DQB1 HLA-DRB1
22 11.8 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
23
Show member pathways
11.77 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10RB IL4
24
Show member pathways
11.66 CD40LG IL4 TNF
25 11.62 CD40LG IL4 TNF
26 11.52 HLA-DPB1 HLA-DQB1 HLA-DRB1
27 11.45 IL10RB IL4 TNF
28 11.22 HLA-DRB1 IL4 TNF
29 11.13 CALR HLA-A HLA-B

GO Terms for Rubella

Cellular components related to Rubella according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.92 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
2 external side of plasma membrane GO:0009897 9.72 CALR CD40LG HLA-DRB1 IL4 TNF
3 trans-Golgi network membrane GO:0032588 9.69 HLA-DPB1 HLA-DQB1 HLA-DRB1
4 phagocytic vesicle membrane GO:0030670 9.63 CALR HLA-A HLA-B
5 endocytic vesicle membrane GO:0030666 9.61 HLA-DPB1 HLA-DQB1 HLA-DRB1
6 cell surface GO:0009986 9.61 C1QBP CALR CD40LG HLA-A HLA-B HLA-DPB1
7 transport vesicle membrane GO:0030658 9.58 HLA-DPB1 HLA-DQB1 HLA-DRB1
8 ER to Golgi transport vesicle membrane GO:0012507 9.55 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
9 clathrin-coated endocytic vesicle membrane GO:0030669 9.54 HLA-DPB1 HLA-DQB1 HLA-DRB1
10 MHC class I protein complex GO:0042612 9.49 HLA-A HLA-B
11 MHC class II protein complex GO:0042613 9.43 HLA-DPB1 HLA-DQB1 HLA-DRB1
12 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
13 plasma membrane GO:0005886 10.22 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DRB1 TRIM5
2 regulation of immune response GO:0050776 9.86 CD40LG HLA-A HLA-B IL4
3 viral process GO:0016032 9.8 C1QBP HLA-A HLA-B HLA-DRB1 MOG TRIM22
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.78 HLA-DPB1 HLA-DQB1 HLA-DRB1
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.78 CD40LG TNF TRIM22 TRIM5
6 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.76 CALR HLA-A HLA-B
7 positive regulation of T cell proliferation GO:0042102 9.74 CD40LG HLA-DPB1 IL4
8 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.73 IL4 TNF TRIM22 TRIM5
9 T cell costimulation GO:0031295 9.67 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1
10 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.63 CALR HLA-A HLA-B
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.61 CALR TNF
12 positive regulation of chemokine biosynthetic process GO:0045080 9.6 IL4 TNF
13 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.59 HLA-A HLA-B
14 positive regulation of dendritic cell chemotaxis GO:2000510 9.58 C1QBP CALR
15 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.55 HLA-DQB1 HLA-DRB1
16 antigen processing and presentation GO:0019882 9.55 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
17 protection from natural killer cell mediated cytotoxicity GO:0042270 9.54 HLA-A HLA-B
18 regulation of immunoglobulin secretion GO:0051023 9.52 CD40LG TNF
19 positive regulation of mononuclear cell migration GO:0071677 9.51 IL4 TNF
20 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.5 HLA-DPB1 HLA-DQB1 HLA-DRB1
21 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TRIM22
22 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.49 HLA-DQB1 HLA-DRB1
23 immune response GO:0006955 9.36 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
2 peptide antigen binding GO:0042605 9.02 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
3 complement component C1q binding GO:0001849 8.96 C1QBP CALR

Sources for Rubella

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....